Behind every medicine is a global team solving complex scientific and operational challenges
Every breakthrough medicine has two stories: the scientific discovery that makes it possible, and the science, engineering and operational expertise required to turn that discovery into a medicine patients can rely on. The second story is rarely told.
Yet for some of the world's most advanced medicines, even a slight change in temperature, light or handling can compromise living cells and delay treatment. When patients are waiting, every moment matters.
Preventing those moments before they happen is the work of Product Development & Supply (PDS). Patients may never know the name Product Development & Supply. But they experience its work every time a medicine is available when they need it.
PDS is Bristol Myers Squibb’s innovation engine, bringing together the expertise, technology and operational capabilities needed to transform scientific discoveries into medicines that improve and extend lives.
As BMS' largest global function, PDS brings together more than 10,000 people across 30+ countries spanning chemistry, engineering, data science, quality, manufacturing and supply. Together, they support nearly 40 medicines and more than 160 clinical assets across biologics, cell therapies, RNA, small molecules, antibody-drug conjugates and emerging modalities.
As science becomes more complex, the systems needed to develop, manufacture and supply medicines must evolve alongside it. PDS continuously advances how medicines reach patients by applying technologies such as predictive supply chain planning, continuous manufacturing and advanced analytics to improve speed, strengthen resilience and increase flexibility across the product lifecycle.
Just as importantly, PDS helps shape medicines with patients' daily lives in mind. Whether developing more convenient formulations, reducing treatment burden or improving how medicines are delivered, teams work to make therapies more accessible and practical for the people who depend on them.
Patients are waiting. Delivering for them means moving with urgency while maintaining the highest standards of quality, safety and compliance. Teams anticipate risks early, solve challenges before they become barriers and use predictive analytics, advanced monitoring and rigorous validation to help ensure reliable performance across development and manufacturing.
These principles are especially important for highly personalized therapies such as CAR T cell therapy, where every day can matter for patients awaiting treatment. Through continuous innovation and process improvements, PDS has helped reduce CAR T turnaround times from approximately six weeks to four weeks.
Beyond just relevant information about Bristol Myers Squibb's therapeutic areas and innovation, Our stories offer a window into the work our employees do every day for patients.
Innovating for patients also means working smarter.
Across PDS, teams use AI and digital technologies to monitor manufacturing in real time, analyze complex scientific data, simulate development approaches and automate documentation, helping identify opportunities sooner and accelerate decision-making. At our Devens, Massachusetts site, these capabilities help teams detect potential issues before they affect production, improving speed, quality and operational performance.
The impact of this work is increasingly being recognized beyond BMS.
In 2026, the Devens site was named to the World Economic Forum's Global Lighthouse Network, joining a select group of facilities recognized for applying advanced technologies at scale.
The site's work also drew national attention when The New York Times explored how manufacturers are using artificial intelligence and highlighted Devens as an example of AI improving pharmaceutical manufacturing.
Delivering medicines tomorrow requires resilient operations as much as scientific innovation. That's why sustainability is embedded throughout PDS, strengthening manufacturing, supply chains and resource use to support reliable medicine delivery for years to come.
For example, teams identified opportunities to shift transportation of biologic medicines between Puerto Rico and Indiana from air freight to ocean freight when appropriate. The change reduced costs and lowered emissions equivalent to planting approximately 20,000 trees, all while maintaining reliable patient supply.
These efforts are about more than reducing environmental impact. They help strengthen supply resilience, improve efficiency and ensure our operations remain capable of supporting patients for decades to come.
Most people will never see the laboratories, manufacturing suites or global supply networks behind a medicine.
They won't see the engineers solving problems before they occur, the scientists analyzing millions of data points or the teams working across continents to keep therapies moving.
Patients don't need to.
They experience the result every time a medicine is ready when they need it.
That's the work of Product Development & Supply.
Because behind every breakthrough medicine is a team committed to delivering for patients.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.
